NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the promotion of Eric Chapdelaine to vice president of manufacturing. According to the update, Chapdelaine’s promotion is a result of the company’s achievement of key manufacturing milestones to support upcoming clinical trials of its lead drug candidate — GPX-001 (quaratusugene ozeplasmid). “The appointment of Eric to our senior team is a hallmark of our manufacturing achievements and highlights the progress we have made in scaling up our manufacturing to commercial scale, which will further supply our upcoming clinical trials,” said Michael Redman, Genprex’s executive vice president and chief operating officer.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer